Electrochemotherapy of gynecological cancers

Institute of Oncology Ljubljana0 个研究点目标入组 30 人开始时间: 2020年2月26日最近更新: 2024年4月22日

适应症

试验速览

暂无简介。

•1. Local or regional recurrences of gynecologic tumors in which standard treatment has been exhausted
•2. Age over 18 years
•3. Life expectancy of more than 3 months
•4. Karnofsky body capacity = 70 or 5. At least 2 weeks have elapsed since the last possible treatment
•6. The patient should be able to understand the treatment process and any side effects that may occur with the treatment
•7. The patient must be able to sign inform consent to participate in the clinical study
•8. Before entering the study, the patient must be presented at the multidisciplinary board
•9. Suitable for procedures in anesthesia

•1. Lesions not suitable for treatment with electrochemotherapy (invasion of bone, infiltration of large vessels)
•2. A life-threatening infection and/or heart failure and/or liver failure and/or other threatening systemic diseases
•3. A significant decline in lung function that requires DLCO determination. We are not allowed to treat patients if DLCO is abnormal
•4. Age under 18 years
•5. Major disruptions in the coagulation system (which do not respond to the standard therapy – supplementation of vitamin K or freshly frozen plasma)
•6. A previously received cumulative dose of bleomycin= 400 mg / m²
•7. A chronic decline in the kidney function (creatinine > 150 µmol/L)
•8. Epilepsy
•9. Pregnancy
•10. The patients’ uncapatibily of comprehending the purpose or course of the trial, or not agreeing to be included in the trial

发起方